TiGenix NV (NYSE Euronext: TIG) is a leading European cell therapy company with a commercial product and a strong clinical stage pipeline of adult stem cell programs. The company’s lead product, ChondroCelect®, for cartilage repair in the knee, is the only approved cell-based product in Europe, and is currently being launched across Europe. TiGenix’s adipose derived allogeneic stem cell platform has been extensively validated. The company has initiated a Phase III clinical trial to treat complex perianal fistulas in patients with Crohn’s disease, has a Phase IIa trial in rheumatoid arthritis ongoing, and has successfully concluded a Phase I trial to investigate intra-lymphatic administration in autoimmune disorders. TiGenix is based out of Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the Netherlands).
22 April 2013 - TiGenix reports positive Phase IIa study results in refractory rheumatoid arthritis with allogeneic stem cell product Cx611 (archived call under MP3) (EN - NL - FR) - Presentation - MP3
World Stem Cell and Regenerative Medicine Congress, Victoria Plaza, London, UK
May 21-23, 2013
BioEquity Europe, Stockholm, Sweden
May 22-23, 2013
Knowledge for Growth, ICC Ghent, Belgium
May 30, 2013